Uncategorized

BioMarin’s new business strategy leaves investors with questions; Lykos CEO steps down; Terns releases compelling data on oral weight loss candidate; and more.

Iowa Total Care, a subsidiary of the St. Louis-based payer, can continue doing business in Iowa’s managed care program, which paid it $2.8 billion in the last fiscal year.

Hospitals continued to add workers to payrolls, while annual wage growth rates stabilized. Both are promising signs for nonprofit and for-profit providers.

The rule gives additional teeth to an almost 16-year-old law meant to force health insurers to cover mental health and substance use benefits at the same level as physical healthcare.

Phase I data for TERN-601 suggests Terns’ oral GLP-1 candidate for obesity could be a contender in the market next to big names like Lilly, Pfizer and Roche.

Vivek Jain, CEO of parent ICU Medical, recently told investors the company has faced more challenges than expected when it bought the Smiths medical device business in 2022.

  En los últimos años, el autoconsumo solar ha emergido como una de las soluciones más efectivas para hogares que desean reducir su dependencia de la red eléctrica convencional. Este sistema permite a los propietarios generar su propia electricidad mediante panele …

Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to develop and commercialize mosliciguat, a potential first-in-class inhaled soluble Guanylate Cyclase activator.

Despite the disappointing late-stage results in non-small cell lung cancer, Jefferies analyst Stephen Barker contends the likelihood of FDA approval “remains high” for the experimental antibody-drug conjugate, though the regulator is now more likely to convene an advisory committee.

Candid Therapeutics, which is repositioning two antibodies for autoimmune indications, will be led by Ken Song who was previously CEO of RayzeBio and oversaw its $4.1 billion acquisition by Bristol Myers Squibb.